Effects of Sitagliptin on Lipid Profile in Patients With Type 2 Diabetes Mellitus After 7 Years of Therapy-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Effects of Sitagliptin on Lipid Profile in Patients With Type 2 Diabetes Mellitus After 7 Years of Therapy

Published:2019-05-26 Issue:10 Volume:59 Page:1391-1399
ISSN:0091-2700
Container-title:The Journal of Clinical Pharmacology
language:en
Short-container-title:The Journal of Clinical Pharmacology

Author:

Derosa Giuseppe¹^ORCID,Tritto Isabella²,Romano Davide¹,D'Angelo Angela¹,Catena Gabriele³,Maffioli Pamela¹

Affiliation:

1. Department of Internal Medicine and TherapeuticsUniversity of Pavia and Fondazione IRCCS Policlinico San Matteo Pavia Italy

2. Department of Cardiology and Cardiovascular PathophysiologyUniversity of Perugia Perugia Italy

3. Cardiologic Unit ASL of Teramo Teramo Italy

Publisher

Wiley

Subject

Pharmacology (medical),Pharmacology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/jcph.1431

Reference24 articles.

1. Diabetes, intermittent claudication, and risk of cardiovascular events. The Framingham Study

2. Diabetes and Vascular Disease: Basic Concepts of Nitric Oxide Physiology, Endothelial Dysfunction, Oxidative Stress and Therapeutic Possibilities

3. Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes

4. Sitagliptin: results from clinical practice

5. Sitagliptin in type 2 diabetes mellitus: Efficacy after five years of therapy

Cited by 9 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A Comparison of the Effects of Empagliflozin and Sitagliptin, When Combined With Metformin, on Lipid Levels in Patients with Type 2 Diabetes: A Clinical Investigation;Cureus;2023-09-05

2. HDL abnormalities in type 2 diabetes: Clinical implications;Atherosclerosis;2023-08

3. A randomized triple-blind controlled clinical trial evaluation of sitagliptin in the treatment of patients with non-alcoholic fatty liver diseases without diabetes;Frontiers in Medicine;2022-07-28

4. Effect of different antidiabetic medications on atherosclerotic cardiovascular disease (ASCVD) risk score among patients with type-2 diabetes mellitus: A multicenter non-interventional observational study;PLOS ONE;2022-06-28

5. Dipeptidyl peptidase IV inhibition delays developmental programming of obesity and metabolic disease in male offspring of obese mothers;Journal of Developmental Origins of Health and Disease;2022-01-24

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3